BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its second quarter 2025 financial results and highlighted recent corporate achievements. "We have strong momentum going into the second half of 2025. We continue to focus on our three core priorities: accelerating revenu ...

Core Insights - Day One Biopharmaceuticals reported a 16% increase in OJEMDA™ (tovorafenib) prescriptions in Q1 2025 compared to Q4 2024, with net product revenue reaching $30.5 million [1][2] - The company ended Q1 2025 with $473.0 million in cash, cash equivalents, and short-term investments [1][5] - Day One is focused on executing its objectives with urgency and fiscal discipline, aiming to create value at every organizational level [2] Financial Performance - OJEMDA net product revenue for Q1 2025 was $30.5 million, an 11% increase in U.S. revenue from Q4 2024 [2][5] - Total revenues for Q1 2025 were $30.8 million, with license revenue from ex-U.S. commercial rights amounting to $0.3 million [5][15] - Research and development expenses were $39.6 million, a slight decrease from $40.2 million in Q1 2024, while selling, general, and administrative expenses rose to $29.3 million from $26.6 million [5][15] - The net loss for Q1 2025 was $36.0 million, a reduction from a net loss of $62.4 million in Q1 2024 [5][15] Product Development and Regulatory Updates - Since its launch, OJEMDA has generated $87.7 million in net product revenue, with over 2,500 prescriptions [2] - The European Medicines Agency accepted the regulatory filing for tovorafenib in April 2025, marking a significant step for its development outside the U.S. [2] - The DAY301 clinical trial has cleared its first dose cohort in the Phase 1a portion, and the pivotal Phase 3 FIREFLY-2 trial is expected to be fully enrolled in the first half of 2026 [2] Upcoming Events - Day One will host a conference call and webcast on May 6, 2025, at 4:30 p.m. ET [1][4] - The company will participate in various upcoming conferences, including the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference and the ASCO Annual Meeting [4][5]